You are here

Trendlines Group still a 'buy': DBS research

dbsr.jpg
DBS Group Research has maintained its buy rating on The Trendlines Group, despite the Catalist-listed medical (medtech) and agricultural tech (agtech) incubator losing the bid to renew its agtech incubator licence.

Singapore

DBS Group Research has maintained its buy rating on The Trendlines Group, despite the Catalist-listed medical (medtech) and agricultural tech (agtech) incubator losing the bid to renew its agtech incubator licence.

It is "not a material loss", DBS analyst Sachin Mittal

sentifi.com

Market voices on:

Powered by GET.comGetCom